Tempus Wealth Planning LLC Makes New Investment in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Tempus Wealth Planning LLC bought a new position in Alphatec Holdings, Inc. (NASDAQ:ATEC) in the third quarter, HoldingsChannel reports. The fund bought 19,165 shares of the medical technology company’s stock, valued at approximately $107,000.

A number of other hedge funds have also bought and sold shares of ATEC. Net Worth Advisory Group purchased a new position in Alphatec in the 3rd quarter worth about $76,000. Comerica Bank increased its position in shares of Alphatec by 64.8% during the 1st quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock valued at $89,000 after purchasing an additional 2,534 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Alphatec by 11.8% during the 2nd quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 1,300 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Alphatec during the 1st quarter valued at about $141,000. Finally, SG Americas Securities LLC increased its position in shares of Alphatec by 44.6% during the 2nd quarter. SG Americas Securities LLC now owns 14,495 shares of the medical technology company’s stock valued at $151,000 after purchasing an additional 4,472 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ATEC shares. Piper Sandler reduced their price target on shares of Alphatec from $17.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Barclays started coverage on shares of Alphatec in a research report on Monday, July 8th. They set an “overweight” rating and a $19.00 price target for the company. Wells Fargo & Company reduced their price target on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Morgan Stanley downgraded Alphatec from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 1st. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 price objective on shares of Alphatec in a research note on Friday, August 30th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Alphatec presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Insider Transactions at Alphatec

In other news, Director David M. Demski acquired 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were acquired at an average cost of $5.67 per share, with a total value of $283,500.00. Following the acquisition, the director now directly owns 288,441 shares of the company’s stock, valued at approximately $1,635,460.47. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 22.80% of the company’s stock.

Alphatec Trading Down 4.6 %

ATEC stock opened at $5.13 on Thursday. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $17.34. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.21. The company has a market capitalization of $717.60 million, a price-to-earnings ratio of -3.44 and a beta of 1.39. The business has a 50 day simple moving average of $5.80 and a two-hundred day simple moving average of $8.99.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.03). Alphatec had a negative return on equity of 816.57% and a negative net margin of 33.48%. The business had revenue of $145.57 million during the quarter, compared to the consensus estimate of $144.55 million. During the same quarter in the previous year, the company earned ($0.43) earnings per share. The company’s revenue for the quarter was up 24.5% compared to the same quarter last year. Research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.